Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects
Open Access
- 8 October 2024
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (10) , e0061324
Abstract
TBAJ-876, a second-generation diarylquinoline with greater antimycobacterial activity and a potentially better safety profile compared with bedaquiline, is under development for the treatment of drug-susceptible and drug-resistant tuberculosis (TB). A phase 1, first-in-human study of TBAJ-876, comprising a single-ascending dose (SAD) part including a food effect cohort, a multiple-ascending dose (MAD) part, and a relative bioavailability part of tablets versus oral suspension, was conducted on 137 healthy adults. A drug–drug interaction study was conducted on 28 healthy adults to evaluate the effects of TBAJ-876 on a cytochrome P450 3A4 substrate (midazolam) and a P-glycoprotein substrate (digoxin). TBAJ-876 was well-tolerated at single doses up to 800 mg and multiple doses up to 200 mg for 14 days. No deaths or serious adverse events occurred. No episodes of clinically significant prolongation of the QTc interval were observed. TBAJ-876 exposures were dose proportional in the SAD and MAD studies. TBAJ-876 exhibited multicompartmental pharmacokinetics (PK) with a long terminal half-life yielding quantifiable concentrations up to the longest follow-up of 10 weeks after a single dose and resulting in accumulation with multiple dosing. In the fed state, TBAJ-876 exposures approximately doubled with the tablet formulation, whereas M3 metabolite exposures decreased by approximately 20%. The relative bioavailability of TBAJ-876 was similar between tablets and the oral suspension at 100-mg doses. With co-administration of TBAJ-876, the AUC 0-inf of midazolam was unchanged and the C max was reduced by 14%; the AUC 0-last of digoxin was increased by 51%, and the C max was increased by 18%. These results support further investigation of TBAJ-876 for the treatment of tuberculosis.Keywords
Funding Information
- Bill and Melinda Gates Foundation
- Department of Foreign Affairs and Trade, Australian Government
- Irish Aid
- United States Agency for International Development
- Foreign, Commonwealth and Development Office
- Bundesministerium für Forschung, Technologie und Raumfahrt
This publication has 6 references indexed in Scilit:
- Emerging bedaquiline resistance: A threat to the global fight against drug-resistant tuberculosisJournal of Biosafety and Biosecurity, 2024
- Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanidPLOS Global Public Health, 2023
- Favorable Outcome of Individual Regimens Containing Bedaquiline and Delamanid in Drug-Resistant Tuberculosis: A Systematic ReviewInternational Journal of Mycobacteriology, 2023
- Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2021
- Bedaquiline: a review of human pharmacokinetics and drug-drug interactionsJournal of Antimicrobial Chemotherapy, 2014
- Confidence Interval Criteria for Assessment of Dose ProportionalityPharmaceutical Research, 2000